In this article, I will feature one healthcare company that has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:
- The stock is purchased by three or more insiders within one month.
- The stock is sold by no insiders in the month of intensive purchasing.
- At least two purchasers increased their holdings by more than 10%.
Galectin Therapeutics (NASDAQ:GALT) engages in the development of therapies for cancer and fibrotic disease.
Insider buying during the last 30 days
Here is a table of Galectin Therapeutics' insider-trading activity during the last 30 days by insider.
|Name||Title||Trade Date||Shares Purchased||Rule 10b5-1 Plan||Current Ownership||Increase In Shares|
|Jack Callicutt||CFO||Nov 19||260||No||260 shares||from 0 to 260|
|Arthur Greenberg||Director||Nov 19||2,000||No||95,667 shares||+2.1%|
|Peter Traber||CEO||Nov 18-19||2,000||No||95,333 shares||+2.1%|
|Kevin Freeman||Director||Nov 18||1,000||No||2,917 shares||+52.2%|
|Harold Shlevin||COO||Nov 18||500||No||53,914 shares||+0.9%|
|James Czirr||Chairman||Nov 15||1,000||No||844,450 shares||+0.1%|
|John Mauldin||Director||Nov 1||478||Yes||21,794 shares||+2.2%|
There have been 7,238 shares purchased by insiders during the last 30 days.
Insider buying by calendar month
Here is a table of Galectin Therapeutics' insider-trading activity by calendar month.
|Month||Insider buying / shares||Insider selling / shares|
There have been 12,607 shares purchased and there have been 112,000 shares sold by insiders this year. The month of November has seen the most insider buying.
Galectin Therapeutics reported the third-quarter financial results on November 12 with the following highlights:
|Net loss||$3.7 million|
Subsequent to quarter end, Galectin Therapeutics received $1.6 million from the exercise of warrants and options, with $1.5 million coming from warrant exercises by 10X Fund L.P. Additionally since September 30, 2013, the company received $0.5 million in net proceeds from the issuance of 50,643 shares through its at market stock issuance program at an average price per share of $10.82.
Galectin Therapeutics believes that the cash on hand at quarter end and already received is sufficient to fund operations and planned research and development into the third quarter of 2014.
Pipeline and upcoming milestones
Galectin Therapeutics is developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the company's unique understanding of galectin proteins, key mediators of biologic function.
(Source: Galectin Therapeutics)
Galectin Therapeutics has the following upcoming data readouts for its fibrosis drug candidate GR-MD-02 currently in Phase 1 trial.
|Cohort 1||Data to be reported Feb-Mar 2014|
|Cohort 2||Data to be reported Jun-Jul 2014|
|Cohort 3||Data to be reported Sept-Oct 2014|
Galectin Therapeutics' competitors in NASH include Raptor Pharmaceuticals (NASDAQ:RPTP), and Intercept Pharmaceuticals (NASDAQ:ICPT). Raptor expects data from its NAFLD Phase 2 trial in the second half of 2014. Intercept expects final results from its Phase 2b NASH trial in late 2014. Here is a table comparing these companies.
Galectin Therapeutics doesn't have any revenues yet.
Here is a table of these competitors' insider-trading activities this year.
|Company||Insider buying / shares||Insider selling / shares|
Only Galectin Therapeutics has seen intensive insider buying during the last 30 days.
There have been seven different insiders buying Galectin Therapeutics and there have not been any insiders selling Galectin Therapeutics during the last 30 days. Two of these seven insiders increased their holdings by more than 10%. Galectin Therapeutics has an insider ownership of 6.60%.
(Source: November presentation)
There are two analyst buy ratings, zero neutral ratings, and zero sell ratings with an average price target of $11.50. The next catalysts for the stock will be the NASH data readouts starting in February 2014. The insiders purchased most of their shares in November around $6, which could be a good entry point for the stock.
(Source: November presentation)